diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5497diaendo-5497Research ArticleСтатьиArticlesРоль аналога человеческого глюкагоноподобногопептида-1 в терапии сахарного диабета 2 типаThe role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitusШестаковаМарина ВладимировнаShestakovaMarina Vladimirovnanephro@endocrincentr.ruФГУ Эндокринологический научный центр, МоскваEndocrinological Research Centre, Moscow201015092010133№3 (2010)106109Copyright © Шестакова М.В., 20102010Шестакова М.В.Shestakova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5497

мае 2010 г. в России зарегистрирован первый аналог человеческого глюкагоноподобного пептида-1 - лираглутид. В обзоре приведеныданные рандомизированных клинических испытаний данного препарата у больных сахарным диабетом 2 типа (СД2) как в монотерапии,так и в комбинации с традиционными сахароснижающими препаратами (программа LEAD 1 - 6). Отмечены преимущества лираглутидав лечении пациентов с избыточной массой тела или ожирением, с сердечно-сосудистыми факторами риска, у больных со склонностьюк гипогликемии. Пациенты, получавшие лираглутид (1,8 мг) чаще, чем пациенты на других сахароснижающих препаратах, достигалисразу нескольких целей терапии: уровня НbА1с<7%, снижения массы тела и контроля артериального давления (АД) (25% против 3 -14% соответственно).

The first human glucagon-like peptide-1 analog (liraglutide) was registered in Russia in May 2010. This review contains data on the results of randomizedclinical studies of this preparation applied to the treatment of patients with DM2 as monotherapy and in combination with traditional hypoglycemicagents (LEAD 1-6 program). Liraglutide is shown to have advantages when used by patients with an excess body mass and obesity, those atrisk of cardiovascular diseases and prone to develop hypoglycemia. Patients treated with liraglutide (1.8 mg) more frequently achieved the desired efficacyendpoints (НbА1с < 7%, reduced body mass and AP control) of than those using traditional therapy (24 vs 3-14%).

инкретиныглюкагоноподобный пептид-1 (ГПП-1)лираглутидВиктозаincretinshuman glucagon-like peptide-1 (GLP-1)liraglutideVictozaReferencesGarber A. Glucagon-like peptide-1 - based therapies: new developments and emerging data. Journal Compilation 2008 Blackwell Publishing Ltd Diabetes // Obesity and Metabolism. - 2008. - 10 (Suppl. 3). - Р. 22-35.Garber A. Glucagon-like peptide-1 - based therapies: new developments and emerging data. Journal Compilation 2008 Blackwell Publishing Ltd Diabetes // Obesity and Metabolism. - 2008. - 10 (Suppl. 3). - Р. 22-35.Nauck M., Stockmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes // Diabetologia 1986; 29: Р. 46-52.Nauck M., Stockmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes // Diabetologia 1986; 29: Р. 46-52.Kolterman O., Kim D.D., Shen L., Ruggles J.A. et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus // Am. J. Health. Syst. Pharm. - 2005. - 62. - Р. 173- 181.Kolterman O., Kim D.D., Shen L., Ruggles J.A. et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus // Am. J. Health. Syst. Pharm. - 2005. - 62. - Р. 173- 181.Vilsbїll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus // Expert Opin. Investig. Drugs. - 2007. - 16. - Р. 231-237.Vilsbїll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus // Expert Opin. Investig. Drugs. - 2007. - 16. - Р. 231-237.Vilsbїll T., Zdravkovic M., Le-Thi T. et al. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus // Diabetes Care. - 2007. - 30. - Р. 1608-1610.Vilsbїll T., Zdravkovic M., Le-Thi T. et al. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus // Diabetes Care. - 2007. - 30. - Р. 1608-1610.Vilsbїll T., Brock B., Perrild H. et al. Liraglutide, a oncedaily human GLP- 1 analogue improves beta-cell function and arginine stimulated insulin secretion at hyperglycaemia in patients with type 2 diabetes mellitus // Diabet. Med. - 2008. - 25. - Р. 152-156.Vilsbїll T., Brock B., Perrild H. et al. Liraglutide, a oncedaily human GLP- 1 analogue improves beta-cell function and arginine stimulated insulin secretion at hyperglycaemia in patients with type 2 diabetes mellitus // Diabet. Med. - 2008. - 25. - Р. 152-156.Vilsbїll T., Zdravkovic M., Le-Thi T. et al. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study // Diabetes. - 2006. - 55 (Suppl. 1). - P.O.Vilsbїll T., Zdravkovic M., Le-Thi T. et al. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study // Diabetes. - 2006. - 55 (Suppl. 1). - P.O.Zinman B. et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD) // Diabetes Care. Published online March 16, 2009 (DOI:10.2337/dc08-2124).Zinman B. et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD) // Diabetes Care. Published online March 16, 2009 (DOI:10.2337/dc08-2124).Garber A. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, doubleblind, parallel-treatment trial // Lancet. - 2009. - 373(9662). - Р. 473-481.Garber A. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, doubleblind, parallel-treatment trial // Lancet. - 2009. - 373(9662). - Р. 473-481.Marre M. et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) // Diabetic Medicine. - 2009. - Р. 268-278.Marre M. et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) // Diabetic Medicine. - 2009. - Р. 268-278.Nauck M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met) // Diabetes Care. - 2009. - 32. - Р. 84-90.Nauck M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met) // Diabetes Care. - 2009. - 32. - Р. 84-90.Russell-Jones D. et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU) // Diabetologia. - 2009. - 52. - Р. 2046-2055.Russell-Jones D. et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU) // Diabetologia. - 2009. - 52. - Р. 2046-2055.Buse J. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, openlabel trial (LEAD-6) // Lancet. - 2009. - 374. - Р. 39-47.Buse J. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, openlabel trial (LEAD-6) // Lancet. - 2009. - 374. - Р. 39-47.Garber A., Henry R. et al. Monotherapy with Liraglutide, a Once-Daily Human GLP-1 Analog, Provides Sustained Reductions in A1C, FPG, and Weight Compared with Glimepiride in Type 2 Diabetes: LEAD-3 mono 2- year // Results Diabetes. - 2009. - 58 (Suppl. 1). - A42 (abstract 162- OR).Garber A., Henry R. et al. Monotherapy with Liraglutide, a Once-Daily Human GLP-1 Analog, Provides Sustained Reductions in A1C, FPG, and Weight Compared with Glimepiride in Type 2 Diabetes: LEAD-3 mono 2- year // Results Diabetes. - 2009. - 58 (Suppl. 1). - A42 (abstract 162- OR).Nauck M., Pratley R. et al. Adding Liraglutide to Existing Therapy ratherthan Substituting it for Existing Therapy Produces Greater Improvement in Glycemic Control: Evidence from a Meta-analysis. // 69th ADA Scientific Sessions Abstract Book. - 2009. - Poster 549.Nauck M., Pratley R. et al. Adding Liraglutide to Existing Therapy ratherthan Substituting it for Existing Therapy Produces Greater Improvement in Glycemic Control: Evidence from a Meta-analysis. // 69th ADA Scientific Sessions Abstract Book. - 2009. - Poster 549.Pratley et al. Liraglutide compared to sitagliptin, both in combination with metformin, in subjects with type 2 diabetes: a 26-week, randomised, parallel- group, open-label trial // Lancet. - 2010. - 375. - Р. 1447- 1456.Pratley et al. Liraglutide compared to sitagliptin, both in combination with metformin, in subjects with type 2 diabetes: a 26-week, randomised, parallel- group, open-label trial // Lancet. - 2010. - 375. - Р. 1447- 1456.Sokos G.G. et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure // J. Card. Fail. - 2006. - 12. - Р. 694-699.Sokos G.G. et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure // J. Card. Fail. - 2006. - 12. - Р. 694-699.Visboll T., Zdravkovic M., Le-Thi et al. Liraglutid treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study // Diabetes. - 2006. - 55 (Suppl. 1).Visboll T., Zdravkovic M., Le-Thi et al. Liraglutid treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study // Diabetes. - 2006. - 55 (Suppl. 1).Дедов И.И., Шестакова М.В. Комментарии ведущих специалистов к статье Влияние лираглютида на биомаркеры сердечно-сосудистого риска у больных СД 2 типа // Болезни сердца и сосудов. - 2009. Том 4, № 2. - С.Дедов И.И., Шестакова М.В. Комментарии ведущих специалистов к статье Влияние лираглютида на биомаркеры сердечно-сосудистого риска у больных СД 2 типа // Болезни сердца и сосудов. - 2009. Том 4, № 2. - С.Zinman B., Buse J. et al. Liraglutide more effectively achieves a composite endpoint for HbA1c, SBP and weight change than other diabetes therapies Liraglutide meta-analyses // 69th ADA Scientific Sessions Abstract Book. - 2009. - Poster 537.Zinman B., Buse J. et al. Liraglutide more effectively achieves a composite endpoint for HbA1c, SBP and weight change than other diabetes therapies Liraglutide meta-analyses // 69th ADA Scientific Sessions Abstract Book. - 2009. - Poster 537.Дедов И.И. Новые возможности терапии сахарного диабета 2 типа // Сахарный диабет. - 2009. - Специальный выпуск. С. 1-3.Дедов И.И. Новые возможности терапии сахарного диабета 2 типа // Сахарный диабет. - 2009. - Специальный выпуск. С. 1-3.

The authors declare that there are no conflicts of interest present.